Genentech cancer drug raises heart risk

	Tweet

An early review of a recent study showed Genentech Inc.’s cancer drug Herceptin can significantly increase the risk of heart problems, the company said in a letter released by U.S. regulators on Wednesday.

The study “demonstrated a significant increase in cardiotoxicity in patients who were randomized to the Herceptin-containing (group) as compared to patients who received chemotherapy alone,” the letter said.

The drug’s label already includes information about possible heart failure and heart ventricle problems. The study aimed to “characterize” the risk and determine the value of continual heart monitoring as a way to detect problems earlier, the letter said.

The randomized, late-stage study of 2,043 breast cancer patients found a higher incidence of damage to the heart muscle, known as cardiac toxicity, in the 1,019 patients taking Herceptin. Such damage can lead to heart failure or even death.

“A statistically significant increase in the 3-year cumulative incidence of...congestive heart failure and cardiac death was observed in patients who received the Herceptin-containing regimen (4.1 percent) compared with control (0.8 percent),” the letter said.

Final analysis of the results, which were first presented at a conference in May, is ongoing, it said.

A Genentech spokeswoman could not be immediately reached for comment.

Genentech sent the undated letter to doctors this month. The U.S. Food and Drug Administration released it on its Web site on Wednesday at http://www.fda.gov/medwatch/safety/2005/HerceptinDDL_0805.FINAL.pdf. 

RELATED STORIES:
Scientists turn skin cells into beating heart muscle   Too many people get angioplasties, study suggests   New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA   Heart Damage After Chemo Linked to Stress in Cardiac Cells   What’s good or bad for the heart, may be the same for the brain   Warfarin in Heart Failure   Increased Sudden Cardiac Death Rate Among HIV Patients   Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease   Lack of basic evidence hampering prevention of sudden heart attacks in sport   Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study   Heart attack patients taken to PCI hospitals first treated faster   Cameron Health’s under-skin ICD safe, effective

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]